{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:25:55Z","timestamp":1764833155338,"version":"3.46.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010609","name":"Gda\u0144ski Uniwersytet Medyczny","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010609","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-stroke depression (PSD) is a common comorbidity following a stroke, often leading to significant emotional and physical disability. While antidepressant medications can alleviate depressive symptoms, treatment resistance is frequently observed in PSD patients. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has shown potential as a treatment for depression due to its neuroprotective, anti-inflammatory, and psychoplastogenic effects. Its effectiveness in treatment-resistant post-stroke depression (TRD-PSD) remains underexplored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two patients diagnosed with treatment-resistant post-stroke depression were treated with intravenous ketamine. Ketamine infusions were administered over a 4-week period in both cases, and the patients\u2019 depressive symptoms were closely monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both patients demonstrated improvement in depressive symptoms following ketamine treatment. The treatment was well tolerated, with minimal side effects reported, and no significant adverse events were observed during the treatment course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better understand the efficacy and safety of ketamine in this specific patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1680687","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:34:04Z","timestamp":1764830044000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Ketamine in post-stroke depression: a report of 2 cases"],"prefix":"10.3389","volume":"16","author":[{"given":"Adam","family":"W\u0142odarczyk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"S\u0142upski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Szarmach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Milewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wies\u0142aw J.","family":"Cuba\u0142a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1192\/bjo.2024.62","article-title":"Guidelines for ketamine use in clinical psychiatry practice","volume":"10","author":"Jelen","year":"2024","journal-title":"BJPsych Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1649503","article-title":"Global burden of stroke","volume":"38","author":"Katan","year":"2018","journal-title":"Semin Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e28137","DOI":"10.7759\/cureus.28137","article-title":"Evaluation and treatment of depression in stroke patients: a systematic review","volume":"14","author":"Lavu","year":"2022","journal-title":"Cureus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17249542","article-title":"Depressed mood after stroke: predictive factors at six months follow-up","volume":"17","author":"L\u00f3pez-Espuela","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.genhosppsych.2020.06.011","article-title":"Post-stroke depression: a 2020 updated review","volume":"66","author":"Medeiros","year":"2020","journal-title":"Gen Hosp Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15596","article-title":"Perspectives for therapy of treatment-resistant depression","volume":"179","author":"Papp","year":"2022","journal-title":"Br J Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.165498","article-title":"Oral ketamine for the treatment of pain and treatment-resistant depression","volume":"208","author":"Schoevers","year":"2016","journal-title":"Br J Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(22)00317-0","article-title":"Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability","volume":"9","author":"Smith-Apeldoorn","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57030274","article-title":"Somatic comorbidities and cardiovascular safety in ketamine use for treatment-resistant depression","volume":"57","author":"Szarmach","year":"2021","journal-title":"Med (Kaunas)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1741504","article-title":"Post-stroke depression: prevalence, associated factors, and relationship to disability in a tertiary care center in Sri Lanka","volume":"13","author":"Thambirajah","year":"2022","journal-title":"J Neurosci Rural Pract"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/bs.apha.2019.03.002","article-title":"Rapid-acting antidepressants","volume":"86","author":"Witkin","year":"2019","journal-title":"Adv Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/pl00002466","article-title":"Ketamine racemate and S-(+)-ketamine: cerebrovascular effects and neuroprotection following focal ischaemia","volume":"46","author":"Werner","year":"1997","journal-title":"Anaesthesist"},{"key":"B16","unstructured":"Clinical investigation of medicinal products in the treatment of depression \u2013 scientific guideline\n          \n          \n          \n          2018"},{"key":"B17","unstructured":"Major depressive disorder: developing drugs for treatment. Guidance for industry\n          \n          \n          \n          2018"},{"key":"B18","unstructured":"Glossary term: adverse event"},{"key":"B19","unstructured":"Glossary term: serious adverse reaction"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00577","article-title":"Poststroke depression biomarkers: A narrative review","volume":"9","author":"Levada","year":"2018","journal-title":"Front Neurol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1595160","article-title":"Post stroke depression: pathogenesis and molecular mechanisms of natural product-based interventions","volume":"16","author":"Gao","year":"2025","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1223145","article-title":"Antidepressant mechanisms of ketamine: a review of actions with relevance to treatment-resistance and neuroprogression","volume":"17","author":"Lullau","year":"2023","journal-title":"Front Neurosci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e26769","DOI":"10.1097\/MD.0000000000026769","article-title":"Dissociative symptoms with intravenous ketamine in treatment-resistant depression: exploratory observational study","volume":"100","author":"W\u0142odarczyk","year":"2021","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/20451253211011021","article-title":"Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression","volume":"11","author":"W\u0142odarczyk","year":"2021","journal-title":"Ther Adv Psychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S337865","article-title":"Preventive approaches for post-stroke depression: where do we stand? A systematic review","volume":"17","author":"Woranush","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121618","article-title":"N-methyl-D-aspartate receptors and depression: linking psychopharmacology, pathology and physiology in a unifying hypothesis for the epigenetic code of neural plasticity","volume":"17","author":"Comai","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1274709","article-title":"Mechanisms associated with post-stroke depression and pharmacologic therapy","volume":"14","author":"Zhan","year":"2023","journal-title":"Front Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-016-0381-0","article-title":"The psychiatric inclusion and exclusion criteria in placebo-controlled monotherapy trials of bipolar depression: an analysis of studies of the past 20 years","volume":"30","author":"Zimmerman","year":"2016","journal-title":"CNS Drugs"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13060909","article-title":"The role of ketamine in the treatment of bipolar depression: A scoping review","volume":"13","author":"Jawad","year":"2023","journal-title":"Brain Sci"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1680687\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:34:06Z","timestamp":1764830046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1680687\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":29,"alternative-id":["10.3389\/fpsyt.2025.1680687"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1680687","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"article-number":"1680687"}}